- Guggenheim has upgraded Ultragenyx Pharmaceutical ( NASDAQ: RARE ) to buy as the company is trading at a discount to its mid-cap biotech peers.
- The firm has a $50 price target (~30% upside based on Wednesday's close).
- Analyst Debjit Chattopadhyay said that the company's commercial franchise and pipeline provide "a floor for the stock close to the current trading level."
- While a clinical update on GTX-102 for Angelman syndrome was underwhelming, Chattopadhyay said that the candidate "could still have legs."
- Seeking Alpha's Quant Rating views Ultragenyx ( RARE ) as a strong sell.
For further details see:
Ultragenyx upgraded to buy at Guggenheim as stock trading at discount to biotech peers